2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2S,3S)-1-((2,2-dimethyl-4-(pivaloyloxy)butoxy)sulfonyl)-2-methyl-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid Trifluoro acetic acid

ID: ALA4549905

PubChem CID: 155550412

Max Phase: Preclinical

Molecular Formula: C26H38F3N5O12S2

Molecular Weight: 619.72

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)OCC(C)(C)CCOC(=O)C(C)(C)C.O=C(O)C(F)(F)F

Standard InChI:  InChI=1S/C24H37N5O10S2.C2HF3O2/c1-13-15(27-17(30)16(14-11-40-21(25)26-14)28-39-24(7,8)19(32)33)18(31)29(13)41(35,36)38-12-23(5,6)9-10-37-20(34)22(2,3)4;3-2(4,5)1(6)7/h11,13,15H,9-10,12H2,1-8H3,(H2,25,26)(H,27,30)(H,32,33);(H,6,7)/b28-16-;/t13-,15-;/m0./s1

Standard InChI Key:  GTVRTKZDFOBGBX-IWGFSSDHSA-N

Molfile:  

     RDKit          2D

 48 48  0  0  0  0  0  0  0  0999 V2000
   29.5798   -3.0954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.2917   -2.6868    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.0035   -3.0954    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   30.2917   -1.8655    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   28.8680   -2.6868    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   29.5798   -3.9167    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   28.8658   -3.5040    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   26.2203   -8.0275    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.8158   -7.3217    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   25.4068   -8.0249    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   27.5245   -6.1991    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.9372   -6.9090    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.3456   -6.1966    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.7653   -6.1496    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.5577   -6.3642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.3474   -5.5706    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.2970   -6.1000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.2970   -6.9172    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.1142   -6.9172    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.1142   -6.1000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.7191   -7.4950    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.6920   -5.5222    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.7191   -5.5222    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.9298   -5.7337    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.3519   -5.1558    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.7183   -6.5230    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   22.5634   -4.3665    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.5626   -5.3673    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.3511   -6.1567    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   20.3502   -7.1575    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.5609   -7.3690    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   20.9281   -7.7354    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   23.3222   -4.0754    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.2795   -3.2593    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4901   -3.0478    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   22.0451   -3.7332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.9146   -2.7450    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.5233   -6.9127    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   27.2312   -7.3208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.6466   -7.3199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.3549   -6.9123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.0621   -7.3218    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   30.7703   -6.9142    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.4775   -7.3238    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.7715   -6.0970    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   31.4764   -8.1410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.1857   -6.9162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.1800   -7.7303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  2  0
  1  5  1  0
  1  6  1  0
  1  7  1  0
  9  8  2  0
 10  9  2  0
 12 11  1  0
 13 12  1  0
 15 14  1  0
 16 15  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 20 17  1  0
 18 21  2  0
 20 22  1  6
 17 23  1  1
 23 24  1  0
 24 25  1  0
 24 26  2  0
 25 27  1  0
 25 28  2  0
 28 29  1  0
 29 15  1  0
 15 30  1  0
 30 31  1  0
 30 32  2  0
 27 33  1  0
 33 34  2  0
 34 35  1  0
 35 36  1  0
 36 27  2  0
 34 37  1  0
 19  9  1  0
  9 38  1  0
 38 39  1  0
 39 12  1  0
 12 40  1  0
 40 41  1  0
 41 42  1  0
 42 43  1  0
 43 44  1  0
 43 45  2  0
 44 46  1  0
 44 47  1  0
 44 48  1  0
M  END

Associated Targets(Human)

CES1 Tchem Acyl coenzyme A:cholesterol acyltransferase (1029 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 619.72Molecular Weight (Monoisotopic): 619.1982AlogP: 1.29#Rotatable Bonds: 13
Polar Surface Area: 216.88Molecular Species: ACIDHBA: 13HBD: 3
#RO5 Violations: 2HBA (Lipinski): 15HBD (Lipinski): 4#RO5 Violations (Lipinski): 2
CX Acidic pKa: 2.87CX Basic pKa: 3.91CX LogP: 2.23CX LogD: -0.50
Aromatic Rings: 1Heavy Atoms: 41QED Weighted: 0.12Np Likeness Score: 0.04

References

1. Gordon EM, Duncton MAJ, Wang BJ, Qi L, Fan D, Li X, Ni ZJ, Ding P, Grygorash R, Low E, Yu G, Sun J..  (2020)  Toward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2.,  11  (2): [PMID:32071683] [10.1021/acsmedchemlett.9b00534]

Source